Table 2.
Pol β protein expression and breast cancer (Nottingham Cohort, n = 1406).
| Variable | POL β protein expression total n = 1406 | P‐valve | |
|---|---|---|---|
| Low N (%) | High N (%) | ||
| A) Pathological parameters | |||
| Tumour size | |||
| <1 cm | 39 (7.2%) | 115 (13.4%) | 0.002 |
| >1–2 cm | 271 (50.4%) | 429 (49.9%) | |
| >2–5 cm | 210 (39.0%) | 297 (34.5%) | |
| >5 cm | 18 (3.3%) | 19 (2.2%) | |
| Tumour stage | |||
| 1 | 327 (60.7%) | 549 (63.7%) | 0.012 |
| 2 | 148 (27.5) | 251 (29.1%) | |
| 3 | 64 (11.9%) | 62 (7.2%) | |
| Tumour grade | |||
| G1 | 58 (10.8%) | 167 (19.4%) | 1.4 × 10−14 |
| G2 | 133 (24.7%) | 326 (37.9%) | |
| G3 | 347 (64.5%) | 367 (42.7%) | |
| Mitotic index | |||
| M1 (low; mitoses < 10) | 122 (22.9%) | 361 (42.1%) | <0.001 |
| M2 (medium; mitoses 10–18) | 84 (15.8%) | 180 (21.0%) | |
| M3 (high; mitosis >18) | 326 (61.3%) | 316 (36.9%) | |
| Pleomorphism | |||
| 1 (Small‐regular uniform) | 9 (1.7%) | 28 (3.3%) | 1.0 × 10−6 |
| 2 (Moderate variation) | 156 (29.4%) | 360 (42.1%) | |
| 3 (Marked variation) | 366 (68.9%) | 468 (54.7%) | |
| Tubule formation | |||
| 1 (>75% of definite tubule) | 15 (2.8%) | 63 (7.4%) | 1.0 × 10−6 |
| 2 (10%–75% definite tubule) | 161 (30.3%) | 291 (34.0%) | |
| 3 (<10% definite tubule) | 356 (66.9%) | 503 (58.7%) | |
| Tumour type | |||
| IDC‐NST | 307 (67.0%) | 402 (54.3%) | 1.4 × 10−5 |
| Tubular carcinoma | 69 (15.1%) | 182 (24.6%) | |
| Medullary carcinoma | 16 (3.5%) | 13 (1.8%) | |
| ILC | 32 (7.0%) | 74 (10.0%) | |
| Others | 34 (7.4%) | 70 (9.4%) | |
| Lymphovascular invasion | |||
| No | 335 (63.7%) | 591 (69.1) | 0.037 |
| Yes | 191 (36.3%) | 264 (30.9%) | |
| B) Aggressive phenotype | |||
| Her2 overexpression | |||
| No | 446 (85.1%) | 757 (90.1%) | 0.005 |
| Yes | 78 (14.9%) | 83 (9.9%) | |
| Triple negative phenotype | |||
| No | 381 (74.0%) | 729 (85.9%) | <0.001 |
| Yes | 134 (26.0%) | 120 (14.1%) | |
| Basal like phenotype | |||
| No | 412 (83.6%) | 753 (90.7%) | 1.1 × 10−4 |
| Yes | 81 (16.4%) | 77 (9.3%) | |
| Cytokeratin 6 (CK6) | |||
| Negative | 355 (79.1%) | 982 (84.4%) | 8.0 × 10−4 |
| Positive | 94 (20.9%) | 182 (15.6%) | |
| Cytokeratin 14 (CK14) | |||
| Negative | 372 (83.8%) | 642 (89.9%) | 0.002 |
| Positive | 72 (16.2%) | 72 (10.1%) | |
| Cytokeratin 18 (CK18) | |||
| Negative | 57 (13.8%) | 57 (8.5%) | 0.006 |
| Positive | 355 (86.2%) | 610 (91.5%) | |
| C) Hormone receptors | |||
| ER | |||
| Negative | 192 (36.9%) | 171 (20.0%) | <0.001 |
| Positive | 329 (63.1%) | 684 (80.0%) | |
| PgR | |||
| Negative | 265 (53.8%) | 284 (35.2%) | <0.001 |
| Positive | 228 (46.2%) | 523 (64.8%) | |
| AR | |||
| Negative | 197 (47.0%) | 201 (30.2%) | <0.001 |
| Positive | 222 (53.0%) | 465 (69.8%) | |
| D) DNA repair | |||
| ATM | |||
| Absent | 178 (54.6%) | 266 (52.8%) | 0.607 |
| Normal | 148 (45.4%) | 238 (47.2%) | |
| BRCA1 | |||
| Absent | 101 (27.4%) | 92 (15.4%) | 5.0 × 10−6 |
| Normal | 267 (72.6%) | 506 (84.6%) | |
| XRCC1 | |||
| Low | 102 (26.1%) | 55 (9.0%) | <0.001 |
| High | 289 (73.9%) | 554 (91.0%) | |
| FEN1 | |||
| Low | 288 (79.3%) | 388 (68.7%) | 3.6 × 10−4 |
| High | 75 (20.7%) | 252 (27.2%) | |
| SMUG1 | |||
| Low | 155 (43.5%) | 188 (34.9%) | 0.010 |
| High | 201 (56.5%) | 350 (65.1%) | |
| E) Cell cycle/apoptosis regulators | |||
| MIB1 | |||
| Low | 125 (28.0%) | 295 (40.9%) | 9 × 10−6 |
| High | 321 (72.0%) | 427 (59.1%) | |
| P53 | |||
| Low expression | 316 (73.7%) | 564 (82.3%) | 0.001 |
| High expression | 113 (26.3%) | 121 (17.7%) | |
| Bcl‐2 | |||
| Negative | 215 (45.6%) | 216 (28.3%) | <0.001 |
| Positive | 257 (54.4%) | 546 (71.7%) | |
| TOP2A | |||
| Low | 193 (51.3%) | 252 (42.1%) | 0.005 |
| Overexpression | 183 (48.7%) | 347 (57.9%) | |
Grade as defined by NGS; BRCA1: Breast cancer 1, early onset; HER2: human epidermal growth factor receptor 2; ER: oestrogen receptor; PgR: progesterone receptor; CK: cytokeratin; Basal‐like: ER−, HER2 and positive expression of either CK5/6, CK14 or EGFR; Triple negative: ER−/PgR‐/HER2‐.